UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 162 filers reported holding UNIQURE NV in Q3 2020. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $329,320 | +87.4% | 49,079 | +220.1% | 0.00% | – |
| Q2 2023 | $175,716 | -42.1% | 15,333 | +1.7% | 0.00% | – |
| Q1 2023 | $303,671 | -12.1% | 15,078 | -1.1% | 0.00% | – |
| Q4 2022 | $345,627 | +18.8% | 15,246 | -1.6% | 0.00% | – |
| Q3 2022 | $291,000 | -14.2% | 15,492 | -14.9% | 0.00% | – |
| Q2 2022 | $339,000 | -21.3% | 18,205 | -23.8% | 0.00% | – |
| Q1 2022 | $431,000 | -45.0% | 23,878 | -36.8% | 0.00% | -100.0% |
| Q4 2021 | $783,000 | -44.2% | 37,767 | -13.8% | 0.00% | 0.0% |
| Q3 2021 | $1,403,000 | +25.4% | 43,822 | +20.6% | 0.00% | 0.0% |
| Q2 2021 | $1,119,000 | +304.0% | 36,334 | +342.1% | 0.00% | – |
| Q1 2021 | $277,000 | -32.4% | 8,219 | -26.2% | 0.00% | -100.0% |
| Q3 2020 | $410,000 | +39.0% | 11,138 | +70.3% | 0.00% | – |
| Q2 2020 | $295,000 | +11.3% | 6,542 | +17.3% | 0.00% | – |
| Q1 2020 | $265,000 | -43.3% | 5,575 | -14.4% | 0.00% | -100.0% |
| Q4 2019 | $467,000 | +49.7% | 6,512 | -17.8% | 0.00% | – |
| Q3 2019 | $312,000 | – | 7,921 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |